Mgr. Lenka Radová, Ph.D.
Senior researcher, Šárka Pospíšilová Research Group
office: bldg. E35/218
Kamenice 753/5
625 00 Brno
phone: | +420 549 49 5841 |
---|---|
e‑mail: |
social and academic networks: |
---|
Total number of publications: 207
2025
-
Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL
HemaSphere, year: 2025, volume: 9, edition: 1, DOI
-
Detection of early relapse in multiple myeloma patients
Cell Division, year: 2025, volume: 20, edition: 1, DOI
-
MicroRNA Analysis in Meningiomas with Different Degrees of Tissue Stiffness: A Potential Tool for Effective Preoperative Planning
Neurosurgery, year: 2025, DOI
-
MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia
Hematological Oncology, year: 2025, DOI
2024
-
A novel thrombocytopenia-4-causing CYCS gene variant decreases caspase activity: Three-generation study
British journal of haematology, year: 2024, volume: 205, edition: 6, DOI
-
CIRCULATING TUMOR CELLS HAVE HIGH PROGNOSTIC SIGNIFICANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH PARASKELETAL OR EXTRAMEDULLARY PLASMACYTOMAS
Year: 2024, type: Conference abstract
-
Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease
Blood Cancer Journal, year: 2024, volume: 14, edition: 1, DOI
-
Del(1p32) is an early and high-risk event in relapsed multiple myeloma patients with extraosseous plasmacytomas
Year: 2024, type: Conference abstract
-
EFFICACY OF IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE REGIMEN IN DARATUMUMAB-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE ANALYSIS
Year: 2024, type: Conference abstract
-
Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis
European Journal of Haematology, year: 2024, volume: 113, edition: 6, DOI